Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

摘要: Abstract In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma patients who had failed conventional therapies. Of 83 assessed at 3 months, following the administration of dose least 1.5 MBq/kg, 75% derived benefit and 22% became free. Symptomatic improvement usually occurred within 6 weeks continued for between 4 15 months (mean months). Based on estimation part this recommended is 150 MBq. Toxicity low, provided platelet levels were above 100 × 1091−1 time treatment. Repeat treatments with may given intervals not less than months. Strontium-89 administered intravenously an out-patient basis no special radiological protection precautions.